Lou Qian,Chen Weixian,Shi Jing,Li Yue,Wang Ding,Zhang Penghui,Li Pu.Clinical significance of CSF-DKK1 as a biomarker for diagnosis and therapeutic monitoring of neuroblastoma[J].J Amry Med Univ (J Third Mil Med Univ),2013,35(15):1587-1590.
Lou Qian,Chen Weixian,Shi Jing,Li Yue,Wang Ding,Zhang Penghui,Li Pu.Clinical significance of CSF-DKK1 as a biomarker for diagnosis and therapeutic monitoring of neuroblastoma[J].J Amry Med Univ (J Third Mil Med Univ),2013,35(15):1587-1590.DOI:
Clinical significance of CSF-DKK1 as a biomarker for diagnosis and therapeutic monitoring of neuroblastoma
Objective To quantitatively detect the cerebrospinal fluid (CSF)-DKK1 (CSF-DKK1) in patients with neuroblastoma (NB)
and to assess the clinical significance of CSF-DKK1 as a biomarker for diagnosis/therapeutic monitoring of NB. Methods The CSF samples were collected from 48 NB pat
ients (experimental group) and 50 patients with other diseases (control group) before and after treatment. In the experimental group
the NB patients were diagnosed by CT scanning and bone marrow examination
including 25 males and 23 females aged from 5 months to 11 years. Evans staging showed that there were 5 patients of phase Ⅰ
20 patients of phase Ⅱ
15 patients of phase Ⅲ and 8 patients of phase Ⅳ. In the control group
there were 25 patients with benign nervous system tumors (13 males and 12 females
aged from 5 months to 65 years)
10 patients with purulent meningitis (4 males and 6 females
aged from 5 months to 6 years) and 15 patients with brain trauma (10 males and 5 females
aged from 2 to 45 years). ELISA was used to quantify the serum level of CSF-DKK1
and ROC analysis was performed. Results Compared with the control group (57.0±13.7 pg/mL)
the level of CSF-DKK1 in patients with NB was increased significantly (88.7±22.9 pg/mL
P
0.01). ROC analysis showed that CSF-DKK1 had a sensitivity of 83% and a specificity of 76% for diagnosis of NB (cut-off=65.0 pg/mL). Compared with those before treatment
the levels of CSF-DKK1 in NB patients (48.5±9.7 pg/mL
n=35) with chemotherapy remission and chemotherapy combined with surgery (46.4±7.8 pg/mL
n=15) was decreased significantly after treatment (
P
0.01). However
the changes of CSF-DKK1 level was not significant in the NB patients with chemotherapy ineffectiveness (89.1±25.7 pg/mL
n=13) (
P
0.05). Conclusion The level of CSF-DKK1 increases significantly in patients with NB
and is closely related to the curative effect of the disease. CSF-DKK1 can be used as a biomarker for auxiliary diagnosis and therapeutic monitoring in patients with NB.